Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer

Lawrence Tamarkin, David Danforth, Alan Lichter, Ernest DeMoss, Michael Cohen, Bruce Chabner, Marc Lippman

Research output: Contribution to journalArticle

189 Scopus citations

Abstract

Plasma melatonin concentrations were determined over a period of 24 hours in 20 women with clinical stage I or II breast cancer. In ten of the patients, whose tumors were estrogen receptor positive, the nocturnal increase in plasma melatonin was much lower than that observed in eight control subjects. Women with the lowest peak concentration of melatonin had tumors with the highest concentrations of estrogen receptors. A significant correlation was found between the peak plasma melatonin concentration and the tumor estrogen receptor concentration in 19 of the patients. These data suggest that low nocturnal melatonin concentrations may indicate the presence of estrogen receptor positive breast cancer and could conceivably have etiologic significance.

Original languageEnglish (US)
Pages (from-to)1003-1005
Number of pages3
JournalScience
Volume216
Issue number4549
DOIs
StatePublished - Jan 1 1982

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Tamarkin, L., Danforth, D., Lichter, A., DeMoss, E., Cohen, M., Chabner, B., & Lippman, M. (1982). Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer. Science, 216(4549), 1003-1005. https://doi.org/10.1126/science.7079745